Hemostemix Licenses CytoImmune's BioReactor Technologies
Hemostemix (HMTXF) has secured a perpetual, royalty-free global license to CytoImmune's Bioreactor stem cell technologies, positioning itself as a leader in the global stem cell market. The company will pay CytoImmune $5,000,000 (twenty million shares) for the license, subject to TSXV Exchange acceptance.
The strategic advantages include achieving the lowest cost of goods sold for allogenic products, creating a protective barrier around autologous stem cell production, and enhancing ACP-01's scalability. The bioreactor technology offers automated cell expansion, high yield efficiency, reduced facility and labor costs, and economies of scale.
This acquisition enables Hemostemix to expand clinical trials, accelerate regulatory approvals, pursue strategic partnerships, and increase profitability through improved gross margins. The technology leverages CytoImmune's expertise in bioreactor design and AI integration for optimized cell production.
Hemostemix (HMTXF) ha ottenuto una licenza globale perpetua e senza royalty per le tecnologie delle cellule staminali Bioreactor di CytoImmune, posizionandosi come leader nel mercato globale delle cellule staminali. L'azienda pagherà a CytoImmune 5.000.000 $ (venti milioni di azioni) per la licenza, soggetta all'accettazione della Borsa TSXV.
I vantaggi strategici includono la realizzazione del costo più basso dei beni venduti per i prodotti allogenici, la creazione di una barriera protettiva attorno alla produzione di cellule staminali autologhe e il miglioramento della scalabilità di ACP-01. La tecnologia del bioreattore offre espansione cellulare automatizzata, alta efficienza di rendimento, riduzione dei costi di struttura e lavoro, e economie di scala.
Questa acquisizione consente a Hemostemix di espandere gli studi clinici, accelerare le approvazioni regolatorie, perseguire partnership strategiche e aumentare la redditività attraverso margini lordi migliorati. La tecnologia sfrutta l'esperienza di CytoImmune nella progettazione di bioreattori e nell'integrazione dell'IA per una produzione cellulare ottimizzata.
Hemostemix (HMTXF) ha asegurado una licencia global perpetua y libre de regalías para las tecnologías de células madre Bioreactor de CytoImmune, posicionándose como líder en el mercado global de células madre. La empresa pagará a CytoImmune 5,000,000 $ (veinte millones de acciones) por la licencia, sujeta a la aceptación de la Bolsa TSXV.
Las ventajas estratégicas incluyen lograr el costo más bajo de bienes vendidos para productos alogénicos, crear una barrera protectora alrededor de la producción de células madre autólogas y mejorar la escalabilidad de ACP-01. La tecnología del bioreactor ofrece expansión celular automatizada, alta eficiencia de rendimiento, reducción de costos de instalaciones y mano de obra, y economías de escala.
Esta adquisición permite a Hemostemix expandir ensayos clínicos, acelerar aprobaciones regulatorias, buscar asociaciones estratégicas y aumentar la rentabilidad a través de márgenes brutos mejorados. La tecnología aprovecha la experiencia de CytoImmune en diseño de bioreactores e integración de IA para una producción celular optimizada.
헤모스테믹스 (HMTXF)는 사이토이뮤니의 바이오리액터 줄기세포 기술에 대한 영구적이고 로열티 없는 글로벌 라이센스를 확보하여 글로벌 줄기세포 시장의 리더로 자리매김하고 있습니다. 이 회사는 라이센스 비용으로 사이토이뮤니에게 5,000,000 달러(2천만 주)를 지불할 예정이며, 이는 TSXV 거래소의 승인을 조건으로 합니다.
전략적 이점으로는 동종 제품의 판매 원가를 최저로 유지하고, 자가 줄기세포 생산 주변에 보호 장벽을 형성하며, ACP-01의 확장성을 향상시키는 것이 포함됩니다. 바이오리액터 기술은 자동화된 세포 확장, 높은 수확 효율성, 시설 및 인건비 절감, 규모의 경제를 제공합니다.
이번 인수는 헤모스테믹스가 임상 시험을 확장하고, 규제 승인을 가속화하며, 전략적 파트너십을 추구하고, 개선된 총 마진을 통해 수익성을 높일 수 있게 합니다. 이 기술은 사이토이뮤니의 바이오리액터 설계 및 AI 통합 전문성을 활용하여 최적화된 세포 생산을 가능하게 합니다.
Hemostemix (HMTXF) a obtenu une licence mondiale perpétuelle et sans redevance pour les technologies de cellules souches Bioreactor de CytoImmune, se positionnant ainsi comme un leader sur le marché mondial des cellules souches. L'entreprise paiera à CytoImmune 5 000 000 $ (vingt millions d'actions) pour la licence, sous réserve de l'acceptation de la Bourse TSXV.
Les avantages stratégiques incluent l'atteinte du coût le plus bas des biens vendus pour les produits allogéniques, la création d'une barrière protectrice autour de la production de cellules souches autologues et l'amélioration de l'évolutivité de l'ACP-01. La technologie du bioreacteur offre une expansion cellulaire automatisée, une efficacité de rendement élevée, une réduction des coûts d'installation et de main-d'œuvre, ainsi que des économies d'échelle.
Cette acquisition permet à Hemostemix d'élargir les essais cliniques, d'accélérer les approbations réglementaires, de rechercher des partenariats stratégiques et d'augmenter la rentabilité grâce à des marges brutes améliorées. La technologie tire parti de l'expertise de CytoImmune en matière de conception de bioreacteurs et d'intégration de l'IA pour une production cellulaire optimisée.
Hemostemix (HMTXF) hat sich eine weltweite, unbefristete und lizenzgebührenfreie Lizenz für die Bioreactor-Stammzelltechnologien von CytoImmune gesichert und positioniert sich damit als führendes Unternehmen im globalen Stammzellmarkt. Das Unternehmen wird CytoImmune 5.000.000 $ (zwanzig Millionen Aktien) für die Lizenz zahlen, vorbehaltlich der Genehmigung durch die TSXV-Börse.
Die strategischen Vorteile umfassen die Erreichung der niedrigsten Kosten für verkaufte Waren bei allogenen Produkten, die Schaffung einer Schutzbarriere rund um die autologen Stammzellproduktion und die Verbesserung der Skalierbarkeit von ACP-01. Die Bioreaktortechnologie bietet automatisierte Zellvermehrung, hohe Ertragseffizienz, reduzierte Anlagen- und Arbeitskosten sowie Skaleneffekte.
Diese Akquisition ermöglicht es Hemostemix, klinische Studien auszuweiten, Genehmigungen durch Regulierungsbehörden zu beschleunigen, strategische Partnerschaften zu verfolgen und die Rentabilität durch verbesserte Bruttomargen zu steigern. Die Technologie nutzt die Expertise von CytoImmune in der Bioreaktorkonstruktion und der KI-Integration zur Optimierung der Zellproduktion.
- Secured perpetual, royalty-free global license for bioreactor technology
- Expected reduction in cost of goods sold through automated production
- Enhanced scalability and efficiency in stem cell production
- Improved competitive position through vertical integration
- Potential for higher gross margins due to lower production costs
- Significant share dilution through $5,000,000 payment in company shares
- License agreement still pending TSXV Exchange acceptance
Calgary, Alberta--(Newsfile Corp. - February 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that secures its leadership position in the global stem cell market. By securing an arm's length perpetual, royalty-free global license to CytoImmune's Bioreactor stem cell technologies, Hemostemix has established an economic and competitive advantage that enhances its ability to scale ACP-01, protect its autologous stem cell market, and create a cost-effective allogenic stem cell expansion strategy.
Subject to the TSXV Exchange acceptance, Hemostemix will pay CytoImmune
Hemostemix's Strategic Advantages from CytoImmune's Bioreactor Technologies License
- Lowest cost of goods sold for allogenic products.
- Strategic fence around autologous stem cell production.
- Scalability and commercial-ability of ACP-01 behind the fence.
Lowest Cost of Goods Sold (COGS) in the Industry
One of the most significant benefits of integrating CytoImmune's Bioreactor technologies into Hemostemix's allogenic stem cell manufacturing processes is the dramatic reduction in the cost of goods sold. Traditional stem cell expansion methods are expensive, labor-intensive, and often reliant on inefficient batch-of-one processing. The key advantages of bioreactor technology include:
- Automated Cell Expansion: Continuous and scalable production reduces manual labor and batch-to-batch variability, ensuring consistent, high-quality stem cell output.
- High Yield & Efficiency: The bioreactor platform maximizes cell proliferation rates, producing exponentially more therapeutic doses per donor-derived stem cell input.
- Reduced Facility and Labor Costs: The efficiency of automated bioreactor systems minimizes the need for extensive cleanroom environments and skilled labor, leading to significant cost reductions.
- Economies of Scale: Mass production becomes feasible at a fraction of the cost of traditional autologous methods.
Building an Allogenic Stem Cell Fence Around Hemostemix's Autologous Market
By leveraging CytoImmune's Bioreactor technologies, Hemostemix secures an allogenic supply of stem cells that strategically complements its autologous offering. This creates a "stem cell fence"—a protective market barrier that prevents competitors from encroaching on Hemostemix's territory.
Here's how:
- Market Domination Through Vertical Integration: With the ability to mass-produce allogenic stem cells at the lowest COGS, Hemostemix can selectively supply stem cell therapies while ensuring its proprietary ACP-01 remains the gold standard for personalized regenerative medicine.
- Regulatory and Competitive Barriers: Owning a perpetual, royalty-free global license ensures no external entity can impose licensing fees, limiting competitors' ability to scale at similar cost efficiencies.
- Dual Market Penetration: Hemostemix retains leadership in autologous treatments while developing allogenic applications to serve broader patient populations and licensing partners.
Scalability and Commercial Growth Behind the Fence
With its allogenic stem cell fence in place, Hemostemix is poised to:
- Expand its Clinical Trials: With low-cost production scalability, Hemostemix can increase the number of indications treated and studied. The Company will announce shortly its clinical trials update.
- Accelerate Regulatory Approvals: Efficient manufacturing supports larger-scale clinical trials, while reducing time-to-market for new applications.
- Pursue Strategic Partnerships & Licensing: Hemostemix gains leverage to negotiate licensing and supply agreements from a position of strength, globally.
- Increase Profitability: Lower COGS translates into higher gross margins and improved financial sustainability.
CytoImmune's Leadership
CytoImmune Therapeutics boasts a team of pioneers in bioreactor design, with extensive experience in applying computational fluid dynamics for optimizing reactor applications ranging from peptides to immune cells, scaling from pilot runs to industrial capacities of up to 20,000 liters. CytoImmune achieved a significant milestone with the first confirmed stirred tank bioreactor design and process for allogeneic T cell production. Additionally, CytoImmune is at the forefront of integrating AI's deep machine learning into bioreactor control systems, enhancing production efficiency for its cells. This combination of expertise in bioreactor technology and AI integration positions CytoImmune as a leader in the biotechnology sector.
Conclusion: A Defensible, Scalable Future for Hemostemix
By securing a perpetual, royalty-free global license to CytoImmune's bioreactor stem cell technologies, Hemostemix has positioned itself as the lowest-cost producer of scalable autologous and allogenic stem cell therapies. This move ensures a defensible, scalable business model that maximizes shareholder value while advancing the promise of regenerative medicine.
"We invite investors to recognize the long-term impact of this milestone as we continue to expand Hemostemix's leadership in the global stem cell market," said Thomas Smeenk, CEO.
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. For more information, please visit www.hemostemix.com.
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder
EM: tsmeenk@hemostemix.com PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the license of CytoImmune's bioreactor technologies, the sales of ACP-01 as an exempt compassionate treatment, the licensing of ACP-01, the Trademark Know Your Health! and related results, including the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis mayface; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression;the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/241530
FAQ
What is the cost of Hemostemix's (HMTXF) CytoImmune license acquisition?
How will the CytoImmune bioreactor technology benefit HMTXF's production costs?
What competitive advantages does the bioreactor license provide to HMTXF?
How will the CytoImmune license impact HMTXF's market position?
